Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 5/20 | 0.33 |
| ▸ | JAK3 | P52333 | 5/20 | 0.33 |
| ▸ | FLT3 | P36888 | 4/20 | 0.33 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.33 |
| ▸ | RIOK2 | Q9BVS4 | 2/20 | 0.33 |
| ▸ | TLK1 | Q9UKI8 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | STK25 | O00506 | 1/20 | 0.33 |
| ▸ | CIT | O14578 | 1/20 | 0.33 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | MUSK | O15146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312134 | 0.92 | KMT2A (0.37) | GRK6JAK2JAK3FLT3RET | |
| SCHEMBL10312188 | 0.91 | JAK2 (0.41) | JAK2JAK3FLT3RETPLK4 | |
| SCHEMBL10312090 | 0.91 | IDH2 (0.39) | GRK6JAK3BTKMELKHRH4 | |
| SCHEMBL10312093 | 0.88 | IGF1R (0.43) | PLK4NTRK1CDK7NTRK3NTRK2 | |
| SCHEMBL10312199 | 0.86 | FLT3 (0.45) | GRK6FLT3CSNK1DCSNK1EMELK | |
| SCHEMBL10312193 | 0.82 | AURKA (0.41) | JAK2JAK3FLT3RETPLK4 | |
| SCHEMBL16556839 | 0.82 | GRK6 (0.33) | GRK6FLT3PLK4EGFRNTRK1 | |
| SCHEMBL10312072 | 0.82 | IDH2 (0.41) | JAK2JAK3FLT3RETPLK4 | |
| SCHEMBL10312099 | 0.81 | HRH4 (0.46) | JAK2JAK3NTRK1HRH4MAPT | |
| SCHEMBL10312155 | 0.80 | IGF1R (0.43) | NTRK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440055-B1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY LLC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | GRK6 101/4885JAK2 176/4885JAK3 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.